Genentech Licenses DualityBio’s DUPAC ADC Platform
Genentech licensed DualityBio’s DUPAC antibody-drug conjugate platform in a deal worth $45 million upfront and more than $1 billion in potential milestones, gaining rights to a novel-payload ADC technology still in early, DualityBio-led preclinical-to-Phase…
